OVARIAN ENDOMETRIOID ADENOCARCINOMA
Clinical trials for OVARIAN ENDOMETRIOID ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new OVARIAN ENDOMETRIOID ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for OVARIAN ENDOMETRIOID ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to extend life in recurrent ovarian cancer
Disease control OngoingThis study looked at whether adding the drug bevacizumab to standard chemotherapy after surgery helps people with recurrent ovarian, peritoneal, or fallopian tube cancer live longer. Over 1,000 participants were randomly assigned to receive chemo alone or chemo plus bevacizumab, …
Matched conditions: OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:50 UTC
-
New hope for Hard-to-Treat ovarian cancer: drug combo shows promise
Disease control OngoingThis study tests whether adding a drug called AZD1775 to standard chemotherapy (gemcitabine) helps women with ovarian, fallopian tube, or peritoneal cancer that has returned and is resistant to platinum-based treatments. About 124 women will be randomly assigned to receive either…
Matched conditions: OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:47 UTC
-
Drug cocktail shows promise for Tough-to-Treat ovarian and breast cancers
Disease control OngoingThis study tests whether combining two drugs—cediranib (which cuts off a tumor's blood supply) and olaparib (which stops cancer cells from repairing themselves)—works better than olaparib alone for people whose ovarian, fallopian tube, peritoneal, or triple-negative breast cancer…
Matched conditions: OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:47 UTC
-
Weekly chemo may improve outcomes for advanced ovarian cancer patients
Disease control OngoingThis study tested two different ways of giving the chemotherapy drug paclitaxel (either once every three weeks or once a week) along with carboplatin, with or without the targeted drug bevacizumab, in 692 people with advanced ovarian, peritoneal, or fallopian tube cancer. The goa…
Matched conditions: OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New drug combo shows promise in ovarian cancer trial
Disease control OngoingThis early-stage trial tests whether adding the drug ipatasertib to standard chemotherapy (paclitaxel and carboplatin) is safe and effective for people with advanced ovarian cancer. About 25 patients with stage III or IV disease will receive the combination before surgery. The go…
Matched conditions: OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Measles virus hijacks stem cells to attack returning ovarian cancer
Disease control OngoingThis study tests a new way to treat ovarian cancer that has come back after standard chemotherapy. Doctors take stem cells from fat tissue, infect them with a specially modified measles virus, and inject them into the belly. The stem cells carry the virus directly to cancer cells…
Matched conditions: OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New drug duo shows promise for Tough-to-Treat ovarian cancer
Disease control OngoingThis study looked at whether combining two targeted drugs (cediranib and olaparib) works better than either drug alone or standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that came back or grew during platinum-based chemo. About 582 women took pa…
Matched conditions: OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
New drug duo targets Hard-to-Treat brain tumors
Disease control OngoingThis early-phase trial tests a new drug (MLN0128) combined with bevacizumab in people with recurrent glioblastoma (a brain cancer) or other advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the safest dose and understand side ef…
Matched conditions: OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
New hope for Hard-to-Treat ovarian cancer: targeted drug combo under study
Disease control OngoingThis study tests whether a new drug combination (bevacizumab plus anetumab ravtansine) works better than standard chemotherapy (bevacizumab plus paclitaxel) for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatme…
Matched conditions: OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:37 UTC